Growth Hormone Hypersecretion in Diabetic Mice
Author Information
Author(s): Peter B. Johansen, Yael Segev, Daniel Landau, Moshe Phillip, Allan Flyvbjerg
Primary Institution: Novo Nordisk A/S, Soroka University Medical Center, Aarhus Kommunehospital
Hypothesis
Streptozotocin diabetic mice will show altered growth hormone and insulin-like growth factor I responses compared to nondiabetic mice.
Conclusion
The study found that STZ diabetic mice exhibit GH hypersecretion and GH resistance, suggesting they may be a better model for studying diabetes than STZ diabetic rats.
Supporting Evidence
- Diabetic mice had significantly higher GH levels after stimulation compared to nondiabetic mice.
- Serum IGF-I levels were lower in diabetic mice and did not increase after stimulation.
- Hepatic GH receptor mRNA levels were significantly lower in diabetic mice.
Takeaway
This study shows that diabetic mice produce too much growth hormone but don't respond well to it, which is similar to what happens in people with type 1 diabetes.
Methodology
The study involved four groups of female Balb/C mice, with two groups made diabetic using streptozotocin, followed by GH secretagogue stimulation and analysis of serum and liver samples.
Potential Biases
Potential bias due to the use of a single high-dose STZ injection for diabetes induction.
Limitations
The study was limited to female mice and may not fully represent male responses.
Participant Demographics
Adult female Balb/C mice, aged unspecified.
Statistical Information
P-Value
p<0.05 for GH levels, p<0.0001 for IGF-I levels.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website